Table 3.

Performance of combing HPV16/18 genotyping with dual-stained cytology versus with Pap cytology in HPV-positive women.

HPV16/18 to colposcopy and triage 12 other HR-HPV(+) with dual-stained cytologyHPV16/18 to colposcopy and triage 12 other HR-HPV(+) with Pap cytology
Positive, n/NEstimate (95% CI)Positive, n/NEstimate (95% CI)P
Detection of CIN2+ (N = 126)
 Sensitivity109/12686.51% (79.3%–91.9%)108/12685.71% (78.4%–91.3%)1.000
 Specificity450/72062.50% (58.8%–66.0%)418/72058.06% (54.4%–61.7%)<0.001
 PPV109/37928.76% (24.2%–33.6%)108/41026.34% (22.1%–30.9%)0.004
 NPV450/46796.36% (94.2%–97.8%)418/43695.87% (93.6%–97.5%)<0.001
Detection of CIN3+ (N = 116)
 Sensitivity101/11687.07% (79.6%–92.6%)100/11686.21% (78.6%–91.9%)1.000
 Specificity452/73061.92% (58.3%–65.5%)420/73057.53% (53.9%–61.2%)<0.001
 PPV101/37926.65% (22.3%–31.4%)100/41024.39% (20.3%–28.8%)0.006
 NPV452/46796.79% (94.8%–98.2%)420/43696.33% (94.1%–97.9%)<0.001
  • Note: P value indicates the comparison between dual-stained cytology and HPV16/18 typing.

  • Abbreviations: CI, confidence interval; HR-HPV, high-risk human papillomavirus.